[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20045312L - Anvendelse av EDG reseptorbindingsmidler ved cancer - Google Patents

Anvendelse av EDG reseptorbindingsmidler ved cancer

Info

Publication number
NO20045312L
NO20045312L NO20045312A NO20045312A NO20045312L NO 20045312 L NO20045312 L NO 20045312L NO 20045312 A NO20045312 A NO 20045312A NO 20045312 A NO20045312 A NO 20045312A NO 20045312 L NO20045312 L NO 20045312L
Authority
NO
Norway
Prior art keywords
cancer
receptor binding
binding agents
edg receptor
sphingosine
Prior art date
Application number
NO20045312A
Other languages
English (en)
Other versions
NO334074B1 (no
Inventor
Jeanette Marjorie Wood
Thomas Baumruker
Volker Brinkmann
Peter Lassota
Kenneth Richard La Montagne
Diana Mechtcheriakova
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0211261A external-priority patent/GB0211261D0/en
Priority claimed from GB0217150A external-priority patent/GB0217150D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20045312L publication Critical patent/NO20045312L/no
Publication of NO334074B1 publication Critical patent/NO334074B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Det beskrives en metode for behandling av faste tumorer, for eksempel tumorinvasivitet og særlig inhibering eller konttollert deregulerte angiogenese, ved bruk av en sflngosinl-fosfatteseptoragonist, eventuelt i kombinasjon med et kjemoterapeutisk middel. Det beskrives videre en kombinasjon av en sfingosin-1-fosfatteseptoragonist med et kjemoterapeutisk middel.
NO20045312A 2002-05-16 2004-12-03 Anvendelse av en S1P reseptoragonist NO334074B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0211261A GB0211261D0 (en) 2002-05-16 2002-05-16 Organic compounds
US39041102P 2002-06-20 2002-06-20
GB0217150A GB0217150D0 (en) 2002-07-24 2002-07-24 Organic compounds
US44973903P 2003-02-24 2003-02-24
PCT/EP2003/005125 WO2003097028A1 (en) 2002-05-16 2003-05-15 Use of edg receptor binding agents in cancer

Publications (2)

Publication Number Publication Date
NO20045312L true NO20045312L (no) 2004-12-03
NO334074B1 NO334074B1 (no) 2013-12-02

Family

ID=29554311

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20045312A NO334074B1 (no) 2002-05-16 2004-12-03 Anvendelse av en S1P reseptoragonist
NO20130106A NO20130106L (no) 2002-05-16 2013-01-17 Anvendelse av EDG reseptorbindingsmidler ved cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20130106A NO20130106L (no) 2002-05-16 2013-01-17 Anvendelse av EDG reseptorbindingsmidler ved cancer

Country Status (23)

Country Link
US (2) US20090209495A1 (no)
EP (3) EP1944026B1 (no)
JP (3) JP5227492B2 (no)
KR (1) KR20120125398A (no)
CN (1) CN1652757B (no)
AT (1) ATE412408T1 (no)
AU (1) AU2003240655B2 (no)
BR (1) BR0311173A (no)
CA (1) CA2483594C (no)
CY (1) CY1108719T1 (no)
DE (1) DE60324416D1 (no)
DK (1) DK1505959T3 (no)
ES (1) ES2316758T3 (no)
HK (2) HK1073606A1 (no)
IL (3) IL164838A (no)
MX (1) MXPA04011384A (no)
NO (2) NO334074B1 (no)
NZ (2) NZ536513A (no)
PL (1) PL372103A1 (no)
PT (1) PT1505959E (no)
SI (1) SI1505959T1 (no)
WO (1) WO2003097028A1 (no)
ZA (1) ZA200408575B (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010688A1 (it) 2001-11-21 2003-05-21 Univ Roma Composti immunoregolatori.
PL211954B1 (pl) 2002-01-11 2012-07-31 Sankyo Co Związek, kompozycja farmaceutyczna oraz zastosowanie kompozycji farmaceutycznej
JP2006505248A (ja) * 2002-06-07 2006-02-16 イーエス・セル・インターナショナル・プライヴェート・リミテッド 幹細胞における分化を制御する方法
CA2515574C (en) * 2003-02-18 2012-03-13 Kyorin Pharmaceutical Co., Ltd. Aminophosphonic acid derivative, salt thereof, and modulator of s1p receptor
GB0500020D0 (en) * 2005-01-04 2005-02-09 Novartis Ag Organic compounds
NZ549162A (en) 2004-02-24 2009-12-24 Sankyo Co Amino-pyrrol alcohol compounds
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US8022225B2 (en) 2004-08-04 2011-09-20 Taisho Pharmaceutical Co., Ltd Triazole derivative
US7241812B2 (en) 2004-08-13 2007-07-10 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
WO2006078336A2 (en) * 2004-10-28 2006-07-27 Lpath Therapeutics, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
GB0513431D0 (en) 2005-06-30 2005-08-10 Kherion Technology Ltd Prophylactic compositions and uses
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
RU2409570C2 (ru) 2006-02-03 2011-01-20 Тайсо Фармасьютикал Ко., Лтд. Производные триазола
PL1988081T3 (pl) 2006-02-06 2013-03-29 Taisho Pharmaceutical Co Ltd Inhibitor wiązania sfingozyno-1-fosforanu
US20090312311A1 (en) * 2006-04-06 2009-12-17 Gary Michael Ksander Combination of organic compounds
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
US8444970B2 (en) * 2006-10-27 2013-05-21 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
PT2177512E (pt) 2007-08-01 2012-05-07 Taisho Pharmaceutical Co Ltd Inibidor da ligação de s1p1
EP2177521A1 (en) 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
BRPI0921533A2 (pt) * 2008-11-11 2016-01-12 Novartis Ag composto orgânicos
EP2356090B1 (en) * 2008-11-11 2017-07-05 Novartis AG Crystalline forms of fingolimod hcl
AU2009331582B2 (en) 2008-12-22 2014-03-13 Novartis Ag Dosage regimen of an S1P receptor agonist
ES2760607T3 (es) 2008-12-22 2020-05-14 Novartis Ag Régimen de dosificación para un agonista del receptor s1p
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
US8766005B2 (en) 2009-07-24 2014-07-01 Ratiopharm Gmbh Process for producing fingolimod salts
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
JP2013505983A (ja) 2009-09-29 2013-02-21 ノバルティス アーゲー Ｓ１ｐ受容体モジュレーターの投与計画
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
WO2012071524A1 (en) 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
FR2968556B1 (fr) 2010-12-13 2013-12-27 Centre Nat Rech Scient Inhibiteurs des infections a vih et leurs utilisations
LT2661261T (lt) 2011-01-07 2019-10-25 Novartis Ag Imunosupresantų kompozicijos
PL2672823T3 (pl) 2011-02-07 2017-02-28 Biogen Ma Inc. Czynniki modulujące działanie receptora s1p
US20150218090A1 (en) 2011-10-21 2015-08-06 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
WO2013094761A1 (ja) * 2011-12-23 2013-06-27 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規s1p受容体調整薬
US10273234B2 (en) 2012-08-06 2019-04-30 Biogen Ma Inc. Compounds that are S1P modulating agents and/or ATX modulating agents
ES2691793T3 (es) 2012-08-06 2018-11-28 Biogen Ma Inc. Derivados de naftaleno 1,5,6-sustituidos como moduladores de receptor de 1-fosfato de esfingosina (S1P) y/o autotaxina (ATX) para tratar trastornos inflamatorios y autoinmunitarios
US9850206B2 (en) 2012-11-20 2017-12-26 Biogen Ma Inc. S1P and/or ATX modulating agents
US9771326B2 (en) 2012-11-20 2017-09-26 Biogen Ma Inc. S1P and/or ATX modulating agents
EP2951148A4 (en) 2013-01-29 2016-09-21 Biogen Ma Inc S1P MODULATING MEDIUM
WO2014152725A1 (en) 2013-03-15 2014-09-25 Biogen Idec Ma Inc. S1p and/or atx modulating agents
CN103417970A (zh) * 2013-08-15 2013-12-04 泰山医学院 雌激素上调内皮系统保护分子鞘氨醇1-磷酸的应用
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
EP3443986A1 (en) 2017-08-17 2019-02-20 AC BioScience Enhancement of chemotherapy efficiency by sphingosine-1-phosphate

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36730A0 (en) * 1970-05-28 1971-06-23 Chemagro Corp Phosphonamidothioates,their preparation and their use as herbicides and/or plant growth regulators
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
DE3372965D1 (en) 1982-07-23 1987-09-17 Ici Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (no) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5604229A (en) * 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
ES2278663T3 (es) 1992-10-28 2007-08-16 Genentech, Inc. Antagonistas del factor de crecimiento de celulas endoteliales vasculares vegf.
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
HUT74686A (en) 1993-12-17 1997-01-28 Sandoz Ag Rapamycin derivatives, their pharmaceutical use, process for producing them and pharmaceutical composition containing them as active agents
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
DE69524962T4 (de) * 1994-08-22 2003-08-28 Mitsubishi Pharma Corp., Osaka Benzolderivate und deren medizinische verwendung
DE122005000053I2 (de) 1995-03-30 2008-01-17 Pfizer Prod Inc Chinazolinderivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
ATE228135T1 (de) 1995-06-09 2002-12-15 Novartis Erfind Verwalt Gmbh Rapamycinderivate
MX9800215A (es) 1995-07-06 1998-03-31 Novartis Ag Pirrolopirimidas y procesos para su preparacion.
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
RO121900B1 (ro) 1996-04-12 2008-07-30 Warner-Lambert Company Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora
DE69734513T2 (de) 1996-06-24 2006-07-27 Pfizer Inc. Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CA2286315C (en) * 1997-04-04 2007-03-06 Yoshitomi Pharmaceutical Industries Ltd. 2-aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6423508B1 (en) * 1998-03-09 2002-07-23 Smithkline Beecham Corporation Polynucleotide sequences of human EDG-1c
AU5620299A (en) 1998-08-11 2000-03-06 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
ATE300957T1 (de) 1998-12-22 2005-08-15 Genentech Inc Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
JP4673977B2 (ja) 1999-03-30 2011-04-20 ノバルティス アーゲー 炎症性疾患治療用フタラジン誘導体
EP1195165A4 (en) * 1999-07-12 2005-08-10 Ono Pharmaceutical Co FIBROSIS INHIBITORS CONTAINING THE ACTIVE INGREDIENT OF SPHINGOSINE A PHOSPHATE OR ITS RECEPTOR AGONISTS
DE60010098T2 (de) 1999-08-24 2005-03-31 Ariad Gene Therapeutics, Inc., Cambridge 28-epirapaloge
PT1254138E (pt) * 2000-02-09 2005-09-30 Novartis Ag Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf
KR100812578B1 (ko) 2000-07-13 2008-03-13 상꾜 가부시키가이샤 아미노알코올 유도체
CA2421893A1 (en) 2000-08-31 2002-03-07 Merck And Co., Inc. Phosphate derivatives as immunoregulatory agents
WO2002045717A1 (en) * 2000-12-06 2002-06-13 Tularik Inc. Lometrexol combination therapy
ES2254675T3 (es) 2001-03-26 2006-06-16 Novartis Ag Derivados del 2-amino-propanol.
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
ATE463478T1 (de) * 2001-09-27 2010-04-15 Kyorin Seiyaku Kk Diaryletherderivat, dessen additionssalz und immunosuppressivum
DE60223699T2 (de) * 2001-09-27 2008-10-30 Kyorin Pharmaceutical Co., Ltd. Diarylsulfidderivat, dessen additionssalz und immunsuppressivum

Also Published As

Publication number Publication date
AU2003240655A1 (en) 2003-12-02
EP1955696B1 (en) 2014-05-28
EP1955696A3 (en) 2011-05-25
CA2483594C (en) 2011-02-15
ES2316758T3 (es) 2009-04-16
IL229550A0 (en) 2014-01-30
HK1126127A1 (en) 2009-08-28
IL229559A0 (en) 2014-01-30
EP1944026A2 (en) 2008-07-16
NO334074B1 (no) 2013-12-02
HK1073606A1 (en) 2005-10-14
KR20120125398A (ko) 2012-11-14
MXPA04011384A (es) 2005-02-14
JP2005529921A (ja) 2005-10-06
JP2013136584A (ja) 2013-07-11
WO2003097028A1 (en) 2003-11-27
IL164838A0 (en) 2005-12-18
US20090209495A1 (en) 2009-08-20
AU2003240655B2 (en) 2007-09-06
EP1955696A2 (en) 2008-08-13
EP1505959A1 (en) 2005-02-16
ZA200408575B (en) 2005-07-27
PT1505959E (pt) 2009-02-05
CN1652757B (zh) 2012-02-08
CY1108719T1 (el) 2014-04-09
PL372103A1 (en) 2005-07-11
DK1505959T3 (da) 2009-02-23
BR0311173A (pt) 2005-03-15
CA2483594A1 (en) 2003-11-27
JP5227492B2 (ja) 2013-07-03
SI1505959T1 (sl) 2009-04-30
DE60324416D1 (de) 2008-12-11
IL164838A (en) 2013-12-31
EP1944026B1 (en) 2013-06-26
ATE412408T1 (de) 2008-11-15
EP1505959B1 (en) 2008-10-29
EP1944026A3 (en) 2011-06-01
US20140303257A1 (en) 2014-10-09
NZ536513A (en) 2007-10-26
JP2010100637A (ja) 2010-05-06
NO20130106L (no) 2004-12-03
CN1652757A (zh) 2005-08-10
NZ560662A (en) 2009-09-25

Similar Documents

Publication Publication Date Title
NO20045312L (no) Anvendelse av EDG reseptorbindingsmidler ved cancer
EP1487436A4 (en) POLYTHERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS
EE05481B1 (et) Kinasoliini derivaadid kasvajate raviks
EP1226823A3 (en) Method of treating certain cancers using an estrogen agonist/antagonist
WO2000004954A3 (de) Neue urokinase-inhibitoren
WO2003093794A3 (en) Methods for discovering tumor biomarkers and diagnosing tumors
AP2004003070A0 (en) The method of treating cancer.
AU2152102A (en) Immunotherapeutic combinations for the treatment of tumors
WO2004031775A3 (en) Method for treating or preventing metastasis of colorectal cancers
GB2379444A9 (en) Assay for cancer of the prostate
AU2228299A (en) Composition and method for treating metastatic tumors or cancer induced by cellsexpressing sv40 tumor antigen
IL160242A0 (en) Methods for the treatment and prognosis of leukemia and other cancer types
WO2002056753A3 (en) P27 prevents cellular migration
CY1114433T1 (el) Χρηση παραγοντων που προσδενονται στον υποδοχεα edg στον καρκινο
WO2004111262A8 (en) Method of identifying a selective chemotherapeutic agent
WO2006045062A3 (en) Pot1 alternative splicing variants
ITGE980008A0 (it) Forno a microonde, in particolare per il trattamento di materiali lapidei o simili.
ITMI20001345A0 (it) Mezzi di aguida per ante scorrevoli.
ES1041190Y (es) Tope magnetico para puertas.
UA49216A (uk) Засіб для лікування ускладнень після видалення злоякісних новоутворень шкіри
ITUD990189A0 (it) Procedimento per la realizzazione di gabbie metalliche e relativa macc hina
GB9905113D0 (en) Chisel and plane-iron renovating and honing guide
HK1061392A1 (en) 5-'4-'2-(N-methyl-n-(2-pyridyl)amino)ethoxyÜbenzylÜthiazolidine-2,4-dione mesylate salt
DK1145011T3 (da) Sammensætninger og fremgangsmåder til diagnosticering og behandling af tumor
FI991173A0 (fi) Menetelmä syöpäriskin detektoimiseksi ja testipakkaus sitä varten

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees